Ticagrelor is a high-quality antiplatelet agent that helps prevent blood cells from sticking together, thereby reducing the risk of harmful blood clots. It is typically prescribed to patients with acute coronary syndrome or a history of myocardial infarction. This ingredient is a vital part of modern cardiovascular generic treatments. Our UK platform ensures secure access to reliable medications containing Ticagrelor for your ongoing heart health.
Ticagrelor is a medication that helps prevent blood clots by keeping platelets from sticking together. It belongs to a group of drugs called antiplatelet agents. In the UK, ticagrelor is most commonly found in the prescription product Brilinta.
The main brand that includes ticagrelor is Brilinta (ticagrelor 90 mg tablets). Brilinta is sold in a variety of pack sizes and can be prescribed as a single-ingredient tablet or in combination with low-dose aspirin. The tablet is taken orally and is the only UK-licensed product that delivers ticagrelor. Generic versions may become available in the future, but at present Brilinta is the recognised formulation.
These uses are authorised by the MHRA and are based on clinical studies that showed a reduction in heart-related complications when ticagrelor is added to standard treatment.
Ticagrelor interferes with a specific signal that tells platelets to clump together. By blocking this signal, the drug makes platelets less sticky, which slows the formation of clots that could block arteries. The effect begins soon after the first dose and is maintained while the medication is taken regularly.
Most people who take ticagrelor notice only mild, short-lasting effects. Typical reports include:
These symptoms usually resolve on their own and do not require medical attention unless they become persistent or worsen.
Although rare, some reactions need urgent care:
If any of these occur, seek emergency help immediately.
People with certain conditions may need extra monitoring or may be advised not to use ticagrelor:
Allergy to ticagrelor or any of the tablet’s inactive ingredients is a contraindication.
Ticagrelor can interact with other medicines and substances that affect blood clotting:
Alcohol can increase the risk of stomach upset, while high-fat meals may delay the drug’s absorption. For a full list of possible interactions, refer to the specific product information for Brilinta.
Store Brilinta tablets in a dry place at room temperature, away from direct sunlight. The medication is usually prescribed for a limited period after an acute cardiac event or a PCI, but the exact length depends on the individual treatment plan. Always follow the instructions that come with your particular tablet and keep the package label for reference. For detailed usage, dosing, and administration, refer to your specific medication’s information.
Antiplatelet agent: A drug that reduces the ability of platelets to stick together, helping to prevent blood clots.
Percutaneous coronary intervention (PCI): A non-surgical procedure that opens narrowed coronary arteries, often using a stent.
Acute coronary syndrome (ACS): A range of conditions, including heart attack and unstable angina, caused by sudden reduced blood flow to the heart.
This article offers general educational information about ticagrelor as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing ticagrelor may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
